Patient-Centric Technology. More Human Experiences.

On World Brain Tumor Day, President and CEO of Medicenna Therapuetics, Inc. Fahar Merchant shed light on the severity of glioblastoma, a fast-growing and aggressive type of brain tumor. "In most cases, you expect the survival outcomes of these patients to be a few weeks to a few months at the most," noted Merchant in an interview with Medidata AI.

One of the biggest challenges, particularly with this type of brain cancer, is that in clinical trials, once a patient is able to make it through to the registration trial and into the pivotal phase 3 study, it's where researchers find that their drugs are failing. While one group will receive the standard of care within a control arm, the other group will get experimental therapy, thus making it very difficult for companies like Medicenna Therapuetics, Inc. to conduct a successful phase 3 clinical trial without having a number of patients drop out from the study.

Watch this video to hear how Medidata AI was able to generate a synthetic control arm, giving Medicenna Therapuetics, Inc. the ability to collect data from patients that had been matched nearly equivalently to the patients treated in their own clinical trial.